Skip to main content

Advertisement

Table 2 Molecular biomarkers that were identified by at least 2 of the approaches with frequency of 100% in any of the three cross-validation rounds

From: Prognostic value of cross-omics screening for kidney clear cell renal cancer survival

Molecular type Molecular biomarker Extreme score stratific. Mean score stratific. Extreme survival stratific. Survival prognosis association
miRNA hsa-mir-10b High expression in better outcome
hsa-mir-130a; hsa-mir-21 High expression in worse outcome
hsa-mir-190; hsa-mir-204; hsa- mir-676   High expression in better outcome
hsa-let-7i   High expression in worse outcome
hsa-mir-130b; hsa-mir-18a; hsa- mir-365-1; hsa-mir-223; hsa- mir-92b   High expression in worse outcome
hsa-mir-3613   High expression in worse outcome
hsa-mir-374b; hsa-mir-590   High expression in worse outcome
mRNA ADH5; ARHGAP24; CLDN10; EHHADH; EIF4EBP2; FBXL5; GIPC2; IMPA2; MFSD4; SALL1; SORBS2; TPRG1L; LRBA; RBM47; RETSAT; RGNEF; SH3BGRL2 High expression in better outcome
AMOT; BBS1; CDC14B; EPHX2; FARS2; KCNJ15; PINK1; RAB3IP; STK32B; ZNF704;   High expression in better outcome
ACADM; ALDH6A1; AMD1; ANK3; ATP11A; C5orf23; CCDC121; CLCN5; CPT2; CRYL1; CYFIP2; DDAH1; DMRTA1; FCHO2l; MAP7; MIA2; MOBKL2B; MRPS18B; NPR3; PANK1; PRKAA2; PRUNE2; SLC16A12; SLC27A2; SPATA18; TFEC; TMEM192; TMEM27; TMEM38B; TOX3; WDR31;   High expression in better outcome
ACOX1; ALDH3A2; HLF; TIMP3; TMEM150C; UFSP2;   High expression in better outcome
Protein AR; CTNNA1; CTNNB1; GAB2 High expression in better outcome
ACACA; CDKN1A; EA15; RAD51 High expression in worse outcome
ERRFI1; IGF1R; MAPK1 MAPK3; SHC1   High expression in better outcome
EEF2   High expression in worse outcome
TSC2   High expression in better outcome
IGFBP2; VASP   High expression in worse outcome
DNA methylation probes cg03032025 (CPEB4)   High methylation in worse outcome
cg14827391 (NXN)
cg15743907 (PDE4DIP)
cg16419354 (FAM163A)
cg24332577 (SALL4)
  High methylation in worse outcome